Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice

Cancer Research

Volumn 63, Issue 3, 2003, Pages 586-592

  Yao, Min ^a   Kargman, Stacia ^b   Lam, Eugene C ^a   Kelly, Colleen R ^a   Zheng, Yaxin ^a   Luk, Pauline ^b   Kwong, Elizabeth ^b   Evans, Jilly F ^c   Wolfe, M Michael ^a,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN D1; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRAFT; CANCER INHIBITION; CANCER RISK; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; FAMILIAL POLYPOSIS; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN TUMOR; SURVIVAL TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; CAMPTOTHECIN; CELL DIVISION; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOSKELETAL PROTEINS; DINOPROSTONE; DRUG SYNERGISM; ENDOTHELIAL GROWTH FACTORS; FLUOROURACIL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-10; INTERLEUKIN-12; ISOENZYMES; LACTONES; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037311125     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Winawer, S. J., Fletcher, R. H., Miller, L., Godlee, F., Stolar, M. H., Mulrow, C. D., Woolf, S. H., Glick, S. N., Ganiats, T. G., Bond, J. H., Rosen, L., Zapka, J. G., Olsen, S. J., Giardiello, F. M., Sisk, J. E., Van Antwerp, R., Brown-Davis, C., Marciniak, D. A., and Mayer, R. J. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology, 112: 594-642, 1997.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352-358, 1990.
3. Ladabaum, U., Chopra, C. L., Huang, G., Scheiman, J. M., Chernew, M. E., and Fendrick, A. M. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann. Intern. Med., 135: 769-781, 2001.
4. Schroy, P. C., III. A Companion to Sleisenger and Fordtran Gastrointestinal Disease, 2000.
5. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
6. Netzer, P., Domek, M., Pai, R., Halter, F., and Tarnawski, A. Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth factor. Aliment. Pharmacol. Ther., 15: 1673-1679, 2001.
7. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulares angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
8. Smalley, W. E., and DuBois, R. N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol., 39: 1-20, 1997.
9. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
10. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M. E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., and Muto, T. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer, 81: 1274-1279, 1999.
11. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231: 232-235, 1971.
12. Wolfe, M. M., Lichtenstein, D. R., and Singh, G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med., 340: 1888-1899, 1999.
13. Masferrer, J. L., Seibert, K., Zweifel, B., and Needleman, P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl. Acad. Sci. USA, 89: 3917-3921, 1992.
14. Kujubu, D. A., Fletcher, B. S., Vamum, B. C., Lim, R. W., and Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 266: 12866-12872, 1991.
15. Tsujii, M., Kawano, S., and DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.
16. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
17. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
18. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
19. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61: 1733-1740, 2001.
20. Yoshimi, N., Kawabata, K., Hara, A., Matsunaga, K., Yamada, Y., and Mori, H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res., 88: 1044-1051, 1997.
21. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
22. Lundholm, K., Gelin, J., Hyltander, A., Lonnroth, C., Sandstrom, R., Svaninger, G., Korner, U., Gulich, M., Karrefors, I., Norli, B., et al. Anti-inflammatory treatment may prolong survival in undemourished patients with metastatic solid tumors. Cancer Res., 54: 5602-5606, 1994.
23. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. (Bethesda), 90: 1529-1536, 1998.
24. Singh, P., Walker, J. P., Townsend, C. M., Jr., and Thompson, J. C. Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c mice. Cancer Res., 46: 1612-1616, 1986.
25. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
26. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
27. Porras, A., Ko, A., Larson, P., Agrawal, N., Woolf, E., Ebel, D., Lassiter, K., Gertz, B., and Schwartz, J. Single and multiple pharmacokinetics [PK] of rofecoxib [R] in healthy subjects. Clin. Pharm. Ther., 67: 137, 2000.
28. Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med., 7: 1041-1047, 2001.
29. Yao, M., Lam, E. C., Kelly, C. R., and Wolfe, M. M. Cyclooxygenase-2 inhibition reduces the proliferative and invasive properties of colorectal adenocarcinoma cells. Gastroenterology, 122: A-240, 2002.
30. Van Cutsem, E., Douillard, J. Y., and Kohne, C. H. Toxicity of irinotecan in patients with colorectal cancer. N. Engl. J. Med., 345: 1351-1352, 2001.
31. Sargent, D. J., Niedzwiecki, D., O'Connell, M. J., and Schilsky, R. L. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med., 345: 144-145: discussion 146, 2001.
32. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284: 1247-1255, 2000.
33. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343: 1520-1528, 2 p following 1528, 2000.
34. Huang, M., Stolina, M., Sharma, S., Mao, J. T., Zhu, L., Miller, P. W., Wollman, J., Herschman, H., and Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res., 58: 1208-1216, 1998.
35. Sharma, S., Stolina, M., Lin, Y., Gardner, B., Miller, P. W., Kronenberg, M., and Dubinett, S. M. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol., 163, 5020-5028, 1999.
36. Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., Lee, J. C., and Dubinett, S. M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol., 164: 361-370, 2000.